Codexis (CDXS) closed at $1.16 on November 13, 2026, up 21.1% from the previous close, on volume of 2,383,777 shares (30-day average 829,709).
Data as of November 13, 2026.
Piper Sandler Sticks to Their Buy Rating for Codexis (CDXS)
TipRanks (Mon, 16-Nov 7:15 AM ET)
TipRanks (Mon, 16-Nov 6:30 AM ET)
Codexis Earnings Call Highlights Growth and Scale-Up Progress
TipRanks (Sat, 14-Nov 10:48 PM ET)
Codexis Q3 GAAP EPS of -$0.08, revenue of $19.26M
Seeking Alpha News (Thu, 12-Nov 4:28 PM ET)
Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 12-Nov 10:00 AM ET)
Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
Globe Newswire (Tue, 10-Nov 6:00 AM ET)
Globe Newswire (Mon, 9-Nov 6:00 AM ET)
Codexis to Report Third Quarter 2026 Financial Results on November 12
Globe Newswire (Thu, 29-Oct 9:00 AM ET)
Globe Newswire (Mon, 28-Sep 6:00 AM ET)
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Codexis trades on the NASDAQ stock market under the symbol CDXS.
As of November 16, 2026, CDXS stock price declined to $1.06 with 727,006 million shares trading.
CDXS has a beta of 2.62, meaning it tends to be more sensitive to market movements. CDXS has a correlation of 0.14 to the broad based SPY ETF.
CDXS has a market cap of $116.08 million. This is considered a Micro Cap stock.
Last quarter Codexis reported $19 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $587,600 and exceeded earnings estimates by $.01.
In the last 3 years, CDXS traded as high as $6.08 and as low as $.90.
The top ETF exchange traded funds that CDXS belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
CDXS has underperformed the market in the last year with a price return of -35.0% while the SPY ETF gained +11.1%. CDXS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.8% and -10.9%, respectively, while the SPY returned -4.7% and -2.2%, respectively.
CDXS support price is $1.09 and resistance is $1.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDXS shares will trade within this expected range on the day.